Dr. Nathan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3300 Gallows Rd
Heart and Lung Transplant
Falls Church, VA 22042Phone+1 703-776-2986Fax+1 703-776-3515
Summary
- Steven D. Nathan, MD, FCCP, is the medical director of Inova's Advanced Lung Disease Program and Lung Transplant Program at Inova Heart and Vascular Institute - Inova Fairfax Medical Campus. He also is a professor at the University of Virginia.
Dr. Nathan is board certified in pulmonary diseases, critical care medicine and internal medicine. The author of more than 500 publications, Dr. Nathan is internationally recognized for his expertise in advanced lung diseases. He is co-editor of two books on idiopathic pulmonary fibrosis that provide pulmonologists and other healthcare workers with an up-to-date review of the background and advances in the field: Idiopathic Pulmonary Fibrosis and Guide to Clinical Management of Idiopathic Pulmonary Fibrosis. He also has written original research manuscripts, abstracts, reviews and book chapters. Dr. Nathan is a reviewer for multiple journals and is on the editorial board for the journal, Thorax. He has served on multiple committees, including U.S. Food and Drug Administration advisory boards as well as steering committees for clinical trials in IPF and pulmonary hypertension, where he has also served as chair.
Dr. Nathan is a member of several professional medical associations, including the American Thoracic Society, the American College of Chest Physicians, and the International Society for Heart and Lung Transplantation. He has delivered talks and been chairperson of numerous sessions at many national and international conferences.
Education & Training
- Cedars-Sinai Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 1988 - 1992
- Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 1985 - 1988
- University of the WitwatersrandClass of 1981
Certifications & Licensure
- CA State Medical License 1988 - Present
- VA State Medical License 1994 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Super Doctor SuperDoctors.com
Clinical Trials
- Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH) Start of enrollment: 2006 May 01
- Treprostinil Combined With Tadalafil for Pulmonary Hypertension Start of enrollment: 2011 Mar 01
- A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations Start of enrollment: 2012 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 2130 citationsA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosisTalmadge E. King, Williamson Z. Bradford, Socorro Castro-Bernardini, Elizabeth A. Fagan, Ian Glaspole
The New England Journal of Medicine. 2014-05-28 - 15 citationsChanges in Neutrophil-Lymphocyte or Platelet-Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary FibrosisSteven D. Nathan, Jayesh Mehta, John L. Stauffer, Elizabeth Morgenthien, Ming Yang
Journal of Clinical Medicine. 2021-04-01 - 71 citationsResequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary FibrosisCamille M. Moore, Rachel Z. Blumhagen, Ivana V. Yang, Avram D Walts, Julie Powers
American Journal of Respiratory and Critical Care Medicine. 2019-07-15
Press Mentions
- First Patient Enrolled in TETON 2 Phase 3 Trial of Tyvaso for IPFOctober 14th, 2022
- United Therapeutics Announces First Patient Enrolled in Phase 3 TETON 2 Study of Tyvaso in Patients with Idiopathic Pulmonary FibrosisOctober 11th, 2022
- Bellerophon Cleared to ‘Downsize’ Patients in PF Study of INOpulseSeptember 30th, 2022
- Join now to see all
External Links
- Dr. Nathan Profilehttps://www.inova.org/doctors/steven-d-nathan-md
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: